

Matthias Cavassini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7628385/publications.pdf>

Version: 2024-02-01

414
papers

17,642
citations

15001

68
h-index

25230

113
g-index

434
all docs

434
docs citations

434
times ranked

18710
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. <i>Lancet HIV</i> , 2017, 4, e349-e356.	2.1	805
2	Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. <i>Aids</i> , 2010, 24, 1243-1250.	1.0	592
3	Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2011, 53, 1130-1139.	2.9	525
4	PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. <i>Nature Medicine</i> , 2016, 22, 754-761.	15.2	388
5	Dominant TNF- α + Mycobacterium tuberculosis-specific CD4+ T cell responses discriminate between latent infection and active disease. <i>Nature Medicine</i> , 2011, 17, 372-376.	15.2	380
6	Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. <i>HIV Medicine</i> , 2013, 14, 195-207.	1.0	329
7	Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to <500 Cells/ μ L in HIV Type 1-Infected Individuals Receiving Potent Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2005, 41, 361-372.	2.9	285
8	Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. <i>British Journal of Cancer</i> , 2010, 103, 416-422.	2.9	276
9	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. <i>Lancet Infectious Diseases</i> , 2016, 16, 43-52.	4.6	256
10	Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV-infected Individuals. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 557-566.	2.3	240
11	CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. <i>Lancet</i> , 2006, 368, 459-465.	6.3	233
12	Factors Associated with the Incidence of Type 2 Diabetes Mellitus in HIV-Infected Participants in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2007, 45, 111-119.	2.9	233
13	Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. <i>Aids</i> , 2015, 29, 221-229.	1.0	208
14	Life expectancy in HIV-positive persons in Switzerland. <i>Aids</i> , 2017, 31, 427-436.	1.0	193
15	Minority Quasispecies of Drug-Resistant HIV-1 That Lead to Early Therapy Failure in Treatment-Naive and Adherent Patients. <i>Clinical Infectious Diseases</i> , 2009, 48, 239-247.	2.9	188
16	Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. <i>Lancet HIV</i> , 2015, 2, e127-e136.	2.1	180
17	Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2010, 15, 413-423.	0.6	172
18	Molecular Epidemiology Reveals Long-Term Changes in HIV Type 1 Subtype B Transmission in Switzerland. <i>Journal of Infectious Diseases</i> , 2010, 201, 1488-1497.	1.9	172

#	ARTICLE	IF	CITATIONS
19	Correlates of Self-Reported Nonadherence to Antiretroviral Therapy in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2006, 41, 385-392.	0.9	156
20	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. <i>Clinical Infectious Diseases</i> , 2014, 58, 1312-1321.	2.9	140
21	Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication. <i>European Journal of Immunology</i> , 2008, 38, 2665-2677.	1.6	138
22	Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2014, 59, 287-297.	2.9	136
23	Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. <i>British Journal of Cancer</i> , 2008, 99, 800-804.	2.9	135
24	In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. <i>Pharmacogenetics and Genomics</i> , 2009, 19, 300-309.	0.7	133
25	Determinants of HIV-1 broadly neutralizing antibody induction. <i>Nature Medicine</i> , 2016, 22, 1260-1267.	15.2	133
26	Ageing with HIV: medication use and risk for potential drug-drug interactions. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2107-2111.	1.3	131
27	Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. <i>HIV Medicine</i> , 2006, 7, 404-410.	1.0	130
28	Role of retroviral restriction factors in the interferon- λ -mediated suppression of HIV-1 in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 3035-3040.	3.3	129
29	Treatment Modification in Human Immunodeficiency Virus-Infected Individuals Starting Combination Antiretroviral Therapy Between 2005 and 2008. <i>Archives of Internal Medicine</i> , 2010, 170, 57.	4.3	127
30	Ambiguous Nucleotide Calls From Population-based Sequencing of HIV-1 are a Marker for Viral Diversity and the Age of Infection. <i>Clinical Infectious Diseases</i> , 2011, 52, 532-539.	2.9	127
31	Incidence and Outcome of Progressive Multifocal Leukoencephalopathy over 20 Years of the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2009, 48, 1459-1466.	2.9	123
32	Hepatitis E Virus Seroprevalence and Chronic Infections in Patients with HIV, Switzerland. <i>Emerging Infectious Diseases</i> , 2011, 17, 1074-1078.	2.0	123
33	Immunogenicity and Safety of Yellow Fever Vaccination for 102 HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2009, 48, 659-666.	2.9	119
34	Risk Factors for Anal Cancer in Persons Infected With HIV: A Nested Case-Control Study in the Swiss HIV Cohort Study. <i>American Journal of Epidemiology</i> , 2013, 178, 877-884.	1.6	116
35	Reducing Tuberculosis Incidence by Tuberculin Skin Testing, Preventive Treatment, and Antiretroviral Therapy in an Area of Low Tuberculosis Transmission. <i>Clinical Infectious Diseases</i> , 2007, 44, 94-102.	2.9	114
36	Humoral Response to the Influenza A H1N1/09 Monovalent AS03-Adjuvanted Vaccine in Immunocompromised Patients. <i>Clinical Infectious Diseases</i> , 2011, 52, 248-256.	2.9	114

#	ARTICLE	IF	CITATIONS
37	Pharmacogenetics-Based Population Pharmacokinetic Analysis of Efavirenz in HIV-1-Infected Individuals. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 85, 485-494.	2.3	113
38	Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART. <i>Nature Communications</i> , 2019, 10, 3193.	5.8	112
39	Evaluation of MRSA-Screen, a Simple Anti-PBP 2a Slide Latex Agglutination Kit, for Rapid Detection of Methicillin Resistance in <i>Staphylococcus aureus</i> . <i>Journal of Clinical Microbiology</i> , 1999, 37, 1591-1594.	1.8	111
40	Tenofovir Use is associated with a Reduction in Calculated Glomerular Filtration Rates in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2007, 12, 1165-1174.	0.6	109
41	High Prevalence of Peripheral Arterial Disease in HIV-Infected Persons. <i>Clinical Infectious Diseases</i> , 2008, 46, 761-767.	2.9	105
42	Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study. <i>HIV Medicine</i> , 2008, 9, 397-405.	1.0	104
43	ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. <i>Pharmacogenetics and Genomics</i> , 2010, 20, 217-230.	0.7	104
44	A LC-MS tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009, 877, 1057-1069.	1.2	101
45	Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. <i>Aids</i> , 2010, 24, 2347-2354.	1.0	101
46	Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. <i>Journal of Hepatology</i> , 2017, 66, 297-303.	1.8	101
47	Self-Reported Non-Adherence to Antiretroviral Therapy Repeatedly assessed by Two Questions Predicts Treatment Failure in Virologically Suppressed Patients. <i>Antiviral Therapy</i> , 2008, 13, 77-86.	0.6	100
48	Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 51, 95-101.	0.8	96
49	Durability and Outcome of Initial Antiretroviral Treatments Received during 2000-2005 by Patients in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2008, 197, 1685-1694.	1.9	95
50	Lipid Profiles for Antiretroviral-Naive Patients Starting Pi- and Nnrti-Based Therapy in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2005, 10, 585-591.	0.6	95
51	Longitudinal Analysis of Patterns and Predictors of Changes in Self-Reported Adherence to Antiretroviral Therapy: Swiss HIV Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 54, 197-203.	0.9	91
52	Association of Pharmacogenetic Markers with Premature Discontinuation of First-line Anti-HIV Therapy: An Observational Cohort Study. <i>Journal of Infectious Diseases</i> , 2011, 203, 246-257.	1.9	89
53	Single-Cell RNA-Seq Reveals Transcriptional Heterogeneity in Latent and Reactivated HIV-Infected Cells. <i>Cell Reports</i> , 2018, 23, 942-950.	2.9	89
54	Hepatitis E Virus Seroprevalence among Blood Donors in Southwest Switzerland. <i>PLoS ONE</i> , 2011, 6, e21150.	1.1	88

#	ARTICLE	IF	CITATIONS
55	Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients. <i>Aids</i> , 2015, 29, 373-383.	1.0	87
56	Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 62, 28-35.	0.9	86
57	Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy. <i>PLoS ONE</i> , 2016, 11, e0160460.	1.1	86
58	Frequency and Determinants of Unprotected Sex among HIV-Infected Persons: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2010, 51, 1314-1322.	2.9	83
59	Population Pharmacokinetics of Atazanavir in Patients with Human Immunodeficiency Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3801-3808.	1.4	82
60	Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. <i>Aids</i> , 2003, 17, F33-F37.	1.0	78
61	HIV Infection Disrupts the Sympatric Host-Pathogen Relationship in Human Tuberculosis. <i>PLoS Genetics</i> , 2013, 9, e1003318.	1.5	78
62	Effect of Early Antiretroviral Therapy during Primary HIV-1 Infection on Cell-Associated HIV-1 Dna and Plasma HIV-1 Rna. <i>Antiviral Therapy</i> , 2011, 16, 535-545.	0.6	77
63	Treatment-Naive Individuals Are the Major Source of Transmitted HIV-1 Drug Resistance in Men Who Have Sex With Men in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2014, 58, 285-294.	2.9	75
64	CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus-Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC). <i>Clinical Infectious Diseases</i> , 2017, 65, 959-966.	2.9	75
65	The Role of Migration and Domestic Transmission in the Spread of HIV-1 Non-B Subtypes in Switzerland. <i>Journal of Infectious Diseases</i> , 2011, 204, 1095-1103.	1.9	74
66	Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection. <i>British Journal of Cancer</i> , 2012, 106, 447-452.	2.9	73
67	The HIV care cascade in Switzerland. <i>Aids</i> , 2015, 29, 2509-2515.	1.0	72
68	Tenofovir use is Associated with an Increase in Serum Alkaline Phosphatase in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2008, 13, 1077-1082.	0.6	71
69	Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study. <i>HIV Medicine</i> , 2009, 10, 407-416.	1.0	70
70	Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009. <i>Aids</i> , 2013, 27, 803-813.	1.0	70
71	Dynamics of HIV Latency and Reactivation in a Primary CD4+ T Cell Model. <i>PLoS Pathogens</i> , 2014, 10, e1004156.	2.1	70
72	Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). <i>International Journal of Epidemiology</i> , 2022, 51, 33-34j.	0.9	69

#	ARTICLE	IF	CITATIONS
73	Hypogonadism in HIV-1-Infected Men is common and does not resolve during antiretroviral therapy. <i>Antiviral Therapy</i> , 2007, 12, 261-266.	0.6	69
74	Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. <i>Aids</i> , 2012, 26, 567-575.	1.0	68
75	Hepatitis B Virus Infection Is Associated With Impaired Immunological Recovery During Antiretroviral Therapy in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2013, 208, 1454-1458.	1.9	67
76	Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 69, 413-421.	0.9	67
77	Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV. <i>Annals of Internal Medicine</i> , 2021, 174, 758-767.	2.0	66
78	Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era. <i>Aids</i> , 2008, 22, 1019-1028.	1.0	64
79	Cohort Profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). <i>International Journal of Epidemiology</i> , 2014, 43, 691-702.	0.9	64
80	A Smoking Cessation Programme in HIV-Infected Individuals: A Pilot Study. <i>Antiviral Therapy</i> , 2006, 11, 787-796.	0.6	63
81	HIV-1 co/super-infection in intravenous drug users. <i>Aids</i> , 2004, 18, 1413-1421.	1.0	62
82	Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu040.	0.4	61
83	Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. <i>Journal of Infectious Diseases</i> , 2015, 212, 28-38.	1.9	61
84	An interdisciplinary HIV-adherence program combining motivational interviewing and electronic antiretroviral drug monitoring. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2011, 23, 550-561.	0.6	60
85	HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2016, 62, 115-122.	2.9	60
86	Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study. <i>HIV Medicine</i> , 2009, 10, 12-18.	1.0	57
87	A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). <i>Aids</i> , 2011, 25, 1481-1487.	1.0	55
88	Molecular characterization of <i>Treponema pallidum</i> subsp. <i>pallidum</i> in Switzerland and France with a new multilocus sequence typing scheme. <i>PLoS ONE</i> , 2018, 13, e0200773.	1.1	55
89	Outbreak of <i>Mycobacterium haemophilum</i> Infections after Permanent Makeup of the Eyebrows. <i>Clinical Infectious Diseases</i> , 2011, 52, 488-491.	2.9	53
90	Improved Virological Outcome in White Patients Infected With HIV-1 Non-B Subtypes Compared to Subtype B. <i>Clinical Infectious Diseases</i> , 2011, 53, 1143-1152.	2.9	53

#	ARTICLE	IF	CITATIONS
91	Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study. <i>Clinical Infectious Diseases</i> , 2016, 62, 1571-1577.	2.9	52
92	Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis. <i>Clinical Infectious Diseases</i> , 2016, 62, 1310-1317.	2.9	52
93	An Analysis of the Benefit of Using HEV Genotype 3 Antigens in Detecting Anti-HEV IgG in a European Population. <i>PLoS ONE</i> , 2013, 8, e62980.	1.1	51
94	Occurrence, risk factors, diagnosis and treatment of syphilis in the prospective observational Swiss HIV Cohort Study. <i>Aids</i> , 2010, 24, 1907-1916.	1.0	49
95	Risk of Cardiovascular Events and Blood Pressure Control in Hypertensive HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 396-404.	0.9	49
96	Adherence as a Predictor of the Development of Class-Specific Resistance Mutations: The Swiss HIV Cohort Study. <i>PLoS ONE</i> , 2013, 8, e77691.	1.1	49
97	Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy. <i>Aids</i> , 2014, 28, 1769-1781.	1.0	48
98	Blood CXCR3+ CD4 T Cells Are Enriched in Inducible Replication Competent HIV in Aviremic Antiretroviral Therapy-Treated Individuals. <i>Frontiers in Immunology</i> , 2018, 9, 144.	2.2	48
99	Determination of Unbound Antiretroviral Drug Concentrations by a Modified Ultrafiltration Method Reveals High Variability in the Free Fraction. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 511-522.	1.0	47
100	Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2016, 214, 399-402.	1.9	47
101	Tracing HIV-1 strains that imprint broadly neutralizing antibody responses. <i>Nature</i> , 2018, 561, 406-410.	13.7	47
102	Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 290-302.	1.3	47
103	CD4 ⁺ T Cell Count Recovery in HIV Type 1-Infected Patients Is Independent of Class of Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2008, 47, 1093-1101.	2.9	46
104	High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013. <i>Journal of Hepatology</i> , 2015, 63, 573-580.	1.8	46
105	Use of <i>Treponema pallidum</i> PCR in Testing of Ulcers for Diagnosis of Primary Syphilis. <i>Emerging Infectious Diseases</i> , 2015, 21, 127-129.	2.0	46
106	Chemsex drugs on the rise: a longitudinal analysis of the Swiss HIV Cohort Study from 2007 to 2017. <i>HIV Medicine</i> , 2020, 21, 228-239.	1.0	46
107	Early Antiretroviral Therapy During Primary HIV-1 Infection Results in a Transient Reduction of the Viral Setpoint upon Treatment Interruption. <i>PLoS ONE</i> , 2011, 6, e27463.	1.1	46
108	A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients. <i>Journal of Mass Spectrometry</i> , 2013, 48, 616-625.	0.7	45

#	ARTICLE	IF	CITATIONS
109	Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2009, 14, 349-357.	0.6	45
110	Long-Term Trends of HIV Type 1 Drug Resistance Prevalence among Antiretroviral Treatment-Experienced Patients in Switzerland. <i>Clinical Infectious Diseases</i> , 2009, 48, 979-987.	2.9	43
111	Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO. <i>Journal of the International AIDS Society</i> , 2014, 17, 19490.	1.2	41
112	Virological Outcome and Management of Persistent Low-Level Viraemia in HIV-1-Infected Patients: 11 Years of the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2015, 20, 165-175.	0.6	41
113	Nonoccupational HIV post-exposure prophylaxis: a 10-year retrospective analysis. <i>HIV Medicine</i> , 2010, 11, 584-592.	1.0	40
114	Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir in HIV-Positive and Healthy Individuals. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2959-2966.	1.4	39
115	A highly virulent variant of HIV-1 circulating in the Netherlands. <i>Science</i> , 2022, 375, 540-545.	6.0	39
116	Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial. <i>Heart</i> , 2008, 95, 385-390.	1.2	38
117	Contribution of Genome-Wide Significant Single-Nucleotide Polymorphisms and Antiretroviral Therapy to Dyslipidemia in HIV-Infected Individuals. <i>Circulation: Cardiovascular Genetics</i> , 2009, 2, 621-628.	5.1	38
118	Successful Efavirenz Dose Reduction Guided by Therapeutic Drug Monitoring. <i>Antiviral Therapy</i> , 2011, 16, 189-197.	0.6	38
119	Seroprevalence of Hepatitis E Virus in Domestic Pigs and Wild Boars in Switzerland. <i>Zoonoses and Public Health</i> , 2014, 61, 537-544.	0.9	38
120	Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv108.	0.4	38
121	CD32 ⁺ and PD-1 ⁺ Lymph Node CD4 T Cells Support Persistent HIV-1 Transcription in Treated Aviremic Individuals. <i>Journal of Virology</i> , 2018, 92, .	1.5	38
122	Polypharmacy, Drug-Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz531.	0.4	38
123	The IFNL3/4 ^{rs3695961} variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients. <i>Aids</i> , 2014, 28, 1885-1889.	1.0	37
124	High Rates of Subsequent Asymptomatic Sexually Transmitted Infections and Risky Sexual Behavior in Patients Initially Presenting With Primary Human Immunodeficiency Virus-1 Infection. <i>Clinical Infectious Diseases</i> , 2018, 66, 735-742.	2.9	37
125	Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity. <i>Molecular Biology and Evolution</i> , 2018, 35, 27-37.	3.5	37
126	Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV. <i>International Journal of Epidemiology</i> , 2014, 43, 887-896.	0.9	36

#	ARTICLE	IF	CITATIONS
127	Privacy-preserving genomic testing in the clinic: a model using HIV treatment. <i>Genetics in Medicine</i> , 2016, 18, 814-822.	1.1	36
128	Factors Associated with the Emergence of K65R in Patients with HIV-1 Infection Treated with Combination Antiretroviral Therapy Containing Tenofovir. <i>Clinical Infectious Diseases</i> , 2008, 46, 1299-1309.	2.9	35
129	Origin of Minority Drug-Resistant HIV-1 Variants in Primary HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2013, 208, 1102-1112.	1.9	35
130	Increases in Condomless Sex in the Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv077-ofv077.	0.4	35
131	Adverse Events to Antiretrovirals in the Swiss HIV Cohort Study: Effect on Mortality and Treatment Modification. <i>Antiviral Therapy</i> , 2007, 12, 1157-1164.	0.6	35
132	A randomized crossover study to compare efavirenz and etravirine treatment. <i>Aids</i> , 2011, 25, 57-63.	1.0	34
133	Hepatitis C infection and the risk of non-liver-related morbidity and mortality in HIV-positive persons in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw809.	2.9	34
134	Dually Active HIV/HBV Antiretrovirals as Protection Against Incident Hepatitis B Infections: Potential for Prophylaxis. <i>Journal of Infectious Diseases</i> , 2016, 214, 599-606.	1.9	34
135	The Presence of Human Immunodeficiency Virus-Associated Neurocognitive Disorders Is Associated With a Lower Adherence to Combined Antiretroviral Treatment. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx070.	0.4	34
136	Neuromyelitis optica following CMV primo-infection. <i>Journal of Internal Medicine</i> , 2007, 261, 500-503.	2.7	32
137	HIV-1 elite controllers: Beware of super-infections. <i>Journal of Clinical Virology</i> , 2010, 47, 376-378.	1.6	32
138	Incidence of HIV-1 Drug Resistance Among Antiretroviral Treatment-Naive Individuals Starting Modern Therapy Combinations. <i>Clinical Infectious Diseases</i> , 2012, 54, 131-140.	2.9	32
139	Participation, characteristics and retention rates of HIV-positive immigrants in the Swiss HIV Cohort Study. <i>HIV Medicine</i> , 2012, 13, 118-126.	1.0	32
140	Rivastigmine for HIV-associated neurocognitive disorders. <i>Neurology</i> , 2013, 80, 553-560.	1.5	32
141	Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	32
142	Is unsafe sexual behaviour increasing among HIV-infected individuals?. <i>Aids</i> , 2004, 18, 1707-1714.	1.0	31
143	Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection. <i>Archives of Internal Medicine</i> , 2012, 172, 1313.	4.3	31
144	Free and Total Plasma Levels of Lopinavir during Pregnancy, at Delivery and Postpartum: Implications for Dosage Adjustments in Pregnant Women. <i>Antiviral Therapy</i> , 2013, 18, 171-182.	0.6	31

#	ARTICLE	IF	CITATIONS
145	Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2489-2498.	1.3	31
146	Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. <i>Lancet HIV</i> , 2017, 4, e486-e494.	2.1	31
147	Late presentation to HIV care despite good access to health services: current epidemiological trends and how to do better. <i>Swiss Medical Weekly</i> , 2016, 146, w14348.	0.8	31
148	NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically infected, ART-treated HIV patients. <i>European Journal of Immunology</i> , 2012, 42, 3038-3048.	1.6	30
149	Neighbourhood socio-economic position, late presentation and outcomes in people living with HIV in Switzerland. <i>Aids</i> , 2015, 29, 231-238.	1.0	30
150	In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors. <i>Journal of Virology</i> , 2016, 90, 1858-1871.	1.5	30
151	High Cure Rates With Grazoprevir-Elbasvir With or Without Ribavirin Guided by Genotypic Resistance Testing Among Human Immunodeficiency Virus/Hepatitis C Virus coinfected Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2019, 68, 569-576.	2.9	30
152	Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers. <i>PLoS ONE</i> , 2017, 12, e0173893.	1.1	30
153	Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. <i>Aids</i> , 2005, 19, 1987-1994.	1.0	29
154	Clinical relevance of cytomegalovirus viraemia*. <i>HIV Medicine</i> , 2011, 12, 394-402.	1.0	29
155	Longer Term Clinical and Virological Outcome of Sub-Saharan African Participants on Antiretroviral Treatment in the Swiss HIV Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 79-85.	0.9	29
156	Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study. <i>BMC Infectious Diseases</i> , 2015, 15, 382.	1.3	29
157	Gender inequalities in the response to combination antiretroviral therapy over time: the Swiss HIV Cohort Study. <i>HIV Medicine</i> , 2015, 16, 319-325.	1.0	29
158	Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. <i>Journal of Experimental Medicine</i> , 2018, 215, 1589-1608.	4.2	29
159	Refining Abacavir Hypersensitivity Diagnoses using a Structured Clinical Assessment and Genetic Testing in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2008, 13, 1019-1028.	0.6	29
160	Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB ₊) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-infection. <i>BMC Infectious Diseases</i> , 2011, 11, 319.	1.3	28
161	Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz330.	0.4	28
162	Ritonavir-Boosted Atazanavir-Lopinavir Combination: A Pharmacokinetic Interaction Study of Total, Unbound Plasma and Cellular Exposures. <i>Antiviral Therapy</i> , 2006, 11, 53-62.	0.6	28

#	ARTICLE	IF	CITATIONS
163	Hepatitis C virus and non-Hodgkin's lymphoma: findings from the Swiss HIV Cohort Study. <i>British Journal of Cancer</i> , 2006, 95, 1598-1602.	2.9	27
164	High Prevalence of Anorectal Chlamydial Infection in HIV-Infected Men Who Have Sex with Men in Switzerland. <i>Clinical Infectious Diseases</i> , 2009, 49, 1532-1535.	2.9	27
165	In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid. <i>Drug Metabolism and Disposition</i> , 2015, 44, 151-161.	1.7	27
166	Viral Diversity Based on Next-Generation Sequencing of HIV-1 Provides Precise Estimates of Infection Recency and Time Since Infection. <i>Journal of Infectious Diseases</i> , 2019, 220, 254-265.	1.9	27
167	Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV. <i>Scientific Reports</i> , 2022, 12, 577.	1.6	27
168	CD4 ⁺ T-Cell Count Increase in HIV-1-Infected Patients with Suppressed Viral Load Within 1 year after start of antiretroviral therapy. <i>Antiviral Therapy</i> , 2007, 12, 889-898.	0.6	27
169	Impact of Single Nucleotide Polymorphisms and of Clinical Risk Factors on New-Onset Diabetes Mellitus in HIV-Infected Individuals. <i>Clinical Infectious Diseases</i> , 2010, 51, 1090-1098.	2.9	26
170	Treatment and Prognosis of AIDS-Related Lymphoma in the Era of Highly Active Antiretroviral Therapy: Findings from the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2007, 12, 931-940.	0.6	26
171	Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1573-1581.	1.3	25
172	Rapid Perturbation in Viremia Levels Drives Increases in Functional Avidity of HIV-specific CD8 T Cells. <i>PLoS Pathogens</i> , 2013, 9, e1003423.	2.1	25
173	Social Meets Molecular: Combining Phylogenetic and Latent Class Analyses to Understand HIV-1 Transmission in Switzerland. <i>American Journal of Epidemiology</i> , 2014, 179, 1514-1525.	1.6	25
174	Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 9-18.	0.7	25
175	The Prevalence of Erectile Dysfunction and Its Association with Antiretroviral Therapy in HIV-Infected Men: The Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2013, 18, 337-344.	0.6	24
176	Long-term Immune Response to Yellow Fever Vaccination in Human Immunodeficiency Virus (HIV)-Infected Individuals Depends on HIV RNA Suppression Status: Implications for Vaccination Schedule. <i>Clinical Infectious Diseases</i> , 2018, 66, 1099-1108.	2.9	24
177	Mortality from suicide among people living with HIV and the general Swiss population: 1988-2017. <i>Journal of the International AIDS Society</i> , 2019, 22, e25339.	1.2	24
178	Changing Trends in International Versus Domestic HCV Transmission in HIV-Positive Men Who Have Sex With Men: A Perspective for the Direct-Acting Antiviral Scale-Up Era. <i>Journal of Infectious Diseases</i> , 2019, 220, 91-99.	1.9	24
179	Determinants of Restoration of CD4 and CD8 Cell Counts and Their Ratio in HIV-1-Positive Individuals With Sustained Virological Suppression on Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 292-300.	0.9	24
180	The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study: baseline participant profile. <i>HIV Medicine</i> , 2020, 21, 30-42.	1.0	24

#	ARTICLE	IF	CITATIONS
181	Blood and Lymph Node Dissemination of Clonal Genome-Intact Human Immunodeficiency Virus 1 DNA Sequences During Suppressive Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2020, 222, 655-660.	1.9	24
182	Viral Suppression Rates in Salvage Treatment With Raltegravir Improved With the Administration of Genotypic Partially Active or Inactive Nucleoside/Tide Reverse Transcriptase Inhibitors. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 57, 24-31.	0.9	23
183	Small Dense Lipoproteins, Apolipoprotein B, and Risk of Coronary Events in HIV-Infected Patients on Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 60, 135-142.	0.9	23
184	Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy. <i>Aids</i> , 2013, 27, 203-210.	1.0	23
185	Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study. <i>Clinical Infectious Diseases</i> , 2017, 64, 1275-1278.	2.9	23
186	Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2690-2697.	1.3	23
187	Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitor-Based Antiretroviral Treatment. <i>Clinical Infectious Diseases</i> , 2021, 73, e2134-e2141.	2.9	23
188	Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPLA™ HIV trial. <i>PLoS Medicine</i> , 2020, 17, e1003421.	3.9	23
189	Antiretroviral adherence program in HIV patients: a feasibility study in the Swiss HIV Cohort Study. <i>International Journal of Clinical Pharmacy</i> , 2010, 32, 776-786.	1.4	22
190	Patterns of Adherence to Raltegravir-Based Regimens and the Risk of Virological Failure Among HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 61, 265-269.	0.9	22
191	Immune response to hepatitis B vaccination in HIV-positive adults with isolated antibodies to HBV core antigen. <i>Journal of Infection</i> , 2012, 65, 157-164.	1.7	22
192	Multiplex Liquid Chromatography-Tandem Mass Spectrometry Assay for Simultaneous Therapeutic Drug Monitoring of Ribavirin, Boceprevir, and Telaprevir. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3147-3158.	1.4	22
193	CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART. <i>Medicine (United States)</i> , 2016, 95, e5094.	0.4	22
194	Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study. <i>Journal of Infectious Diseases</i> , 2020, 222, 637-645.	1.9	22
195	Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV. <i>Journal of Mass Spectrometry</i> , 2020, 55, e4506.	0.7	22
196	Increased macrophage migration inhibitory factor (MIF) plasma levels in acute HIV-1 infection. <i>Cytokine</i> , 2012, 60, 338-340.	1.4	21
197	<sc>HIV</sc>-infected patients' beliefs about their chronic co-treatments in comparison with their combined antiretroviral therapy. <i>HIV Medicine</i> , 2018, 19, 49-58.	1.0	21
198	Outcomes of Antiretroviral Therapy in the Swiss HIV Cohort Study: Latent Class Analysis. <i>AIDS and Behavior</i> , 2012, 16, 245-255.	1.4	20

#	ARTICLE	IF	CITATIONS
199	Suboptimal access to primary healthcare among street-based sex workers in southwest Switzerland. <i>Postgraduate Medical Journal</i> , 2013, 89, 371-375.	0.9	20
200	Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naïve patients. <i>Aids</i> , 2014, 28, 2231-2239.	1.0	20
201	Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv026.	0.4	20
202	The Interplay Between Host Genetic Variation, Viral Replication, and Microbial Translocation in Untreated HIV-Infected Individuals. <i>Journal of Infectious Diseases</i> , 2015, 212, 578-584.	1.9	20
203	Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw009.	0.4	20
204	Cross-Sectional and Cumulative Longitudinal Central Nervous System Penetration Effectiveness Scores Are Not Associated With Neurocognitive Impairment in a Well Treated Aging Human Immunodeficiency Virus-Positive Population in Switzerland. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz277.	0.4	20
205	Discontinuation of maintenance therapy against toxoplasma encephalitis in AIDS patients with sustained response to anti-retroviral therapy. <i>Clinical Microbiology and Infection</i> , 2006, 12, 666-671.	2.8	19
206	The Individualized Genetic Barrier Predicts Treatment Response in a Large Cohort of HIV-1 Infected Patients. <i>PLoS Computational Biology</i> , 2013, 9, e1003203.	1.5	19
207	Micro-Structural Brain Alterations in Aviremic HIV+ Patients with Minor Neurocognitive Disorders: A Multi-Contrast Study at High Field. <i>PLoS ONE</i> , 2013, 8, e72547.	1.1	19
208	Missed opportunities for HIV testing among patients newly presenting for HIV care at a Swiss university hospital: a retrospective analysis. <i>BMJ Open</i> , 2018, 8, e019806.	0.8	19
209	HIV-1 Drug Resistance Transmission Networks in Southwest Switzerland. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 1233-1238.	0.5	18
210	A cross-sectional survey of attitudes to HIV risk and rapid HIV testing among clients of sex workers in Switzerland. <i>Sexually Transmitted Infections</i> , 2012, 88, 462-464.	0.8	18
211	HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons. <i>BMC Gastroenterology</i> , 2015, 15, 79.	0.8	18
212	Liver fibrosis in treatment-naïve HIV-infected and HIV/HBV co-infected patients: Zambia and Switzerland compared. <i>International Journal of Infectious Diseases</i> , 2016, 51, 97-102.	1.5	18
213	Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV. <i>Aids</i> , 2020, 34, 103-108.	1.0	18
214	Repeated Syphilis Episodes in HIV-Infected Men Who Have Sex With Men: A Multicenter Prospective Cohort Study on Risk Factors and the Potential Role of Syphilis Immunity. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa019.	0.4	18
215	Forgiveness of Dolutegravir-Based Triple Therapy Compared With Older Antiretroviral Regimens: A Prospective Multicenter Cohort of Adherence Patterns and HIV-RNA Replication. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab316.	0.4	18
216	Impact of Previous Virological Treatment Failures and Adherence on the Outcome of Antiretroviral Therapy in 2007. <i>PLoS ONE</i> , 2009, 4, e8275.	1.1	18

#	ARTICLE	IF	CITATIONS
217	Comparison of HIV-infected patients' characteristics, healthcare resources use and cost between native and migrant patients. <i>International Journal of Public Health</i> , 2009, 54, 5-10.	2.7	17
218	Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study*. <i>HIV Medicine</i> , 2011, 12, 279-288.	1.0	17
219	Adherence to Antiretroviral Treatment Decreases During Postpartum Compared to Pregnancy: A Longitudinal Electronic Monitoring Study. <i>AIDS Patient Care and STDs</i> , 2013, 27, 208-210.	1.1	17
220	Association of disclosure of HIV status with medication adherence. <i>Patient Education and Counseling</i> , 2016, 99, 1413-1420.	1.0	17
221	Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study. <i>Virus Evolution</i> , 2018, 4, vey024.	2.2	17
222	Impact of Direct-Acting Antivirals on the Burden of HCV Infection Among Persons Who Inject Drugs and Men Who Have Sex With Men in the Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy154.	0.4	17
223	HAART and the heart: changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapy. <i>Journal of Internal Medicine</i> , 2007, 261, 255-267.	2.7	16
224	<i>Histoplasma capsulatum</i> var. <i>duboisii</i> infection in a patient with AIDS: rapid diagnosis using polymerase chain reaction-sequencing. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 64, 85-89.	0.8	16
225	Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens. <i>PLoS ONE</i> , 2012, 7, e50307.	1.1	16
226	Higher Risk of Incident Hepatitis C Virus Coinfection Among Men Who Have Sex With Men, in Whom the HIV Genetic Bottleneck at Transmission Was Wide. <i>Journal of Infectious Diseases</i> , 2014, 210, 1555-1561.	1.9	16
227	Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis. <i>ELife</i> , 2017, 6, .	2.8	16
228	Targeted versus non-targeted HIV testing offered via electronic questionnaire in a Swiss emergency department: A randomized controlled study. <i>PLoS ONE</i> , 2018, 13, e0190767.	1.1	16
229	Lymph node migratory dendritic cells modulate HIV-1 transcription through PD-1 engagement. <i>PLoS Pathogens</i> , 2019, 15, e1007918.	2.1	16
230	Association of Incomplete Adherence to Antiretroviral Therapy With Cardiovascular Events and Mortality in Virologically Suppressed Persons With HIV: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab032.	0.4	16
231	Plasma leptin levels in men are not related to the development of lipotrophy during antiretroviral therapy. <i>Aids</i> , 2005, 19, 1837-1842.	1.0	15
232	Minor Protease Inhibitor Mutations at Baseline Do Not Increase the Risk for a Virological Failure in HIV-1 Subtype B Infected Patients. <i>PLoS ONE</i> , 2012, 7, e37983.	1.1	15
233	An analysis of patients' understanding of "routine" preoperative blood tests and HIV screening. Is no news really good news?. <i>HIV Medicine</i> , 2012, 13, 439-443.	1.0	15
234	Patients with AIDS-defining cancers are not universally screened for HIV: a 10-year retrospective analysis of HIV testing practices in a Swiss university hospital. <i>HIV Medicine</i> , 2014, 15, 631-634.	1.0	15

#	ARTICLE	IF	CITATIONS
235	Performance of the 47-Kilodalton Membrane Protein versus DNA Polymerase I Genes for Detection of <i>Treponema pallidum</i> by PCR in Ulcers. <i>Journal of Clinical Microbiology</i> , 2015, 53, 976-980.	1.8	15
236	Genotypic Resistance Tests Sequences Reveal the Role of Marginalized Populations in HIV-1 Transmission in Switzerland. <i>Scientific Reports</i> , 2016, 6, 27580.	1.6	15
237	Ability to Work and Employment Rates in Human Immunodeficiency Virus (HIV)-1-Infected Individuals Receiving Combination Antiretroviral Therapy: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw022.	0.4	15
238	Impact of screening and antiretroviral therapy on anal cancer incidence in HIV-positive MSM. <i>Aids</i> , 2017, 31, 1859-1866.	1.0	15
239	Low Current and Nadir CD4 ⁺ T-Cell Counts are Associated with Higher Hepatitis C virus RNA Levels in the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2008, 13, 455-460.	0.6	15
240	Gynecomastia and potent antiretroviral therapy. <i>Aids</i> , 2004, 18, 1347-1349.	1.0	14
241	HIV Testing Practices by Clinical Service before and after Revised Testing Guidelines in a Swiss University Hospital. <i>PLoS ONE</i> , 2012, 7, e39299.	1.1	14
242	Qualitative analysis of barriers and facilitators encountered by HIV patients in an ART adherence programme. <i>International Journal of Clinical Pharmacy</i> , 2014, 36, 716-724.	1.0	14
243	Postnatal retention in HIV care: insight from the Swiss HIV Cohort Study over a 15-year observational period. <i>HIV Medicine</i> , 2016, 17, 280-288.	1.0	14
244	Patient and doctor perspectives on HIV screening in the emergency department: A prospective cross-sectional study. <i>PLoS ONE</i> , 2017, 12, e0180389.	1.1	14
245	Long terms trends in CD4 ⁺ cell counts, CD8 ⁺ cell counts, and the CD4+. <i>Aids</i> , 2018, 32, 1361-1367.	1.0	14
246	How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population?. <i>HIV Medicine</i> , 2020, 21, 342-348.	1.0	14
247	Cause-specific mortality after diagnosis of cancer among HIV-positive patients: A collaborative analysis of cohort studies. <i>International Journal of Cancer</i> , 2020, 146, 3134-3146.	2.3	14
248	Analysis of inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study reveals gender inequity. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 758-764.	1.3	14
249	Cost-Effectiveness of Enfuvirtide for Treatment-Experienced Patients with HIV in Italy. <i>HIV Clinical Trials</i> , 2005, 6, 92-102.	2.0	13
250	Androgen and gonadotropin patterns differ in HIV-1-infected men who develop lipodystrophy during antiretroviral therapy: a case-control study. <i>HIV Medicine</i> , 2008, 9, 427-432.	1.0	13
251	Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study. <i>HIV Medicine</i> , 2011, 12, 299-307.	1.0	13
252	Tuberculosis in HIV-Negative and HIV-Infected Patients in a Low-Incidence Country: Clinical Characteristics and Treatment Outcomes. <i>PLoS ONE</i> , 2012, 7, e34186.	1.1	13

#	ARTICLE	IF	CITATIONS
253	Cryptococcus neoformans meningitis with negative cryptococcal antigen: Evaluation of a new immunochromatographic detection assay. <i>New Microbes and New Infections</i> , 2015, 4, 1-4.	0.8	13
254	Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1933-1942.	1.3	13
255	Development of an algorithm for analysing the electronic measurement of medication adherence in routine HIV care. <i>International Journal of Clinical Pharmacy</i> , 2016, 38, 1210-1218.	1.0	13
256	The relationship of smoking and unhealthy alcohol use to the HIV care continuum among people with HIV in an integrated health care system. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108481.	1.6	13
257	Long-term safety of discontinuation of secondary prophylaxis against <i>Pneumocystis pneumonia</i> . <i>Aids</i> , 2004, 18, 2047-2053.	1.0	12
258	Randomized trial of a computerized coronary heart disease risk assessment tool in HIV-infected patients receiving combination antiretroviral therapy. <i>Antiviral Therapy</i> , 2010, 15, 31-40.	0.6	12
259	Predicting smoking cessation and its relapse in HIV-infected patients: the Swiss HIV Cohort Study. <i>HIV Medicine</i> , 2015, 16, 3-14.	1.0	12
260	Rapid decline of anti-hepatitis C virus (HCV) antibodies following early treatment of incident HCV infections in HIV-infected men who have sex with men. <i>HIV Medicine</i> , 2018, 19, 420-425.	1.0	12
261	Dietary Patterns and Physical Activity Correlate With Total Cholesterol Independently of Lipid-Lowering Drugs and Antiretroviral Therapy in Aging People Living With Human Immunodeficiency Virus. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy067.	0.4	12
262	Random forest machine learning algorithm predicts virologic outcomes among HIV infected adults in Lausanne, Switzerland using electronically monitored combined antiretroviral treatment adherence. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 530-536.	0.6	12
263	Anti-apolipoprotein A-1 autoantibodies are associated with immunodeficiency and systemic inflammation in HIV patients. <i>Journal of Infection</i> , 2018, 76, 186-195.	1.7	12
264	Cardiovascular risk assessment in people living with HIV compared to the general population. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 689-699.	0.8	12
265	Hemophagocytic syndrome after highly active antiretroviral therapy initiation: a life-threatening event related to immune restoration inflammatory syndrome?. <i>Aids</i> , 2008, 22, 549-551.	1.0	11
266	No Longitudinal Mitochondrial DNA Sequence Changes in HIV-infected Individuals With and Without Lipoatrophy. <i>Journal of Infectious Diseases</i> , 2011, 203, 620-624.	1.9	11
267	Long-Term Close Follow-up of Chorioretinal Lesions in Presumed Ocular Tuberculosis. <i>European Journal of Ophthalmology</i> , 2012, 22, 195-202.	0.7	11
268	Changes in Biomarkers of Liver Disease during Successful Combination Antiretroviral Therapy in HIV-HCV-Coinfected Individuals. <i>Antiviral Therapy</i> , 2014, 19, 149-159.	0.6	11
269	Human papillomavirus antibody response following HAART initiation among MSM. <i>Aids</i> , 2017, 31, 561-569.	1.0	11
270	Antiretroviral Drugs Associated With Subclinical Coronary Artery Disease in the Swiss Human Immunodeficiency Virus Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 70, 884-889.	2.9	11

#	ARTICLE	IF	CITATIONS
271	Higher Memory Responses in HIV-Infected and Kidney Transplanted Patients than in Healthy Subjects following Priming with the Pandemic Vaccine. <i>PLoS ONE</i> , 2012, 7, e40428.	1.1	11
272	Long-Term Virological Response to Multiple Sequential Regimens of Highly Active Antiretroviral Therapy for HIV Infection. <i>Antiviral Therapy</i> , 2004, 9, 263-274.	0.6	11
273	Peripheral oedema and high arterial blood flow as a complication of antiretroviral therapy. <i>Aids</i> , 2004, 18, 356-358.	1.0	10
274	Associations Between Antiretroviral Treatment and Avascular Bone Necrosis: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx177.	0.4	10
275	No Effect of Pegylated Interferon- α on Total HIV-1 DNA Load in HIV-1/HCV Coinfected Patients. <i>Journal of Infectious Diseases</i> , 2018, 217, 1883-1888.	1.9	10
276	Determination of nucleosidic/tidic reverse transcriptase inhibitors in plasma and cerebrospinal fluid by ultra-high-pressure liquid chromatography coupled with tandem mass spectrometry. <i>Clinical Mass Spectrometry</i> , 2018, 8, 8-20.	1.9	10
277	UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1125, 121733.	1.2	10
278	Emergence of Drug Resistance in the Swiss HIV Cohort Study Under Potent Antiretroviral Therapy Is Observed in Socially Disadvantaged Patients. <i>Clinical Infectious Diseases</i> , 2020, 70, 297-303.	2.9	10
279	Phylogenetic Cluster Analysis Identifies Virological and Behavioral Drivers of Human Immunodeficiency Virus Transmission in Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2021, 72, 2175-2183.	2.9	10
280	Awareness of HIV Testing Guidelines Is Low among Swiss Emergency Doctors: A Survey of Five Teaching Hospitals in French-Speaking Switzerland. <i>PLoS ONE</i> , 2013, 8, e72812.	1.1	10
281	Patients' understanding of blood tests and attitudes to HIV screening in the emergency department of a Swiss teaching hospital: a cross-sectional observational study. <i>Swiss Medical Weekly</i> , 2015, 145, w14206.	0.8	10
282	Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study. <i>Lancet HIV</i> , 2022, 9, e404-e413.	2.1	10
283	How reliable is an undetectable viral load?. <i>HIV Medicine</i> , 2009, 10, 470-476.	1.0	9
284	Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV. <i>Antiviral Therapy</i> , 2009, 14, 771-779.	0.6	9
285	High prevalence of physical inactivity among patients from the Swiss HIV Cohort Study. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2017, 29, 1056-1061.	0.6	9
286	Neglect of attention to reproductive health in women with HIV infection: contraceptive use and unintended pregnancies in the Swiss HIV Cohort Study. <i>HIV Medicine</i> , 2018, 19, 339-346.	1.0	9
287	IL-4 polymorphism influences susceptibility to <i>Pneumocystis jirovecii</i> pneumonia in HIV-positive patients. <i>Aids</i> , 2019, 33, 1719-1727.	1.0	9
288	Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 468-472.	1.3	9

#	ARTICLE	IF	CITATIONS
289	Prevalence of Potential Drug-Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase Inhibitors. <i>Clinical Infectious Diseases</i> , 2021, 73, e2145-e2152.	2.9	9
290	A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®. <i>Trials</i> , 2021, 22, 724.	0.7	9
291	Ecological Study of the Predictors of Successful Management of Dyslipidemia in HIV-Infected Patients on ART: the Swiss HIV Cohort Study. <i>HIV Clinical Trials</i> , 2007, 8, 77-85.	2.0	8
292	Treatment of 5q-syndrome with lenalidomide in an HIV-positive patient under cART. <i>Annals of Hematology</i> , 2010, 89, 425-426.	0.8	8
293	Periurethral abscess complicating gonococcal urethritis: case report and literature review. <i>Infection</i> , 2010, 38, 497-500.	2.3	8
294	Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort Study. <i>Journal of Translational Medicine</i> , 2011, 9, 14.	1.8	8
295	Lipid and Lipoprotein Profile in HIV-Infected Patients Treated with Lopinavir/Ritonavir as a Component of the First Combination Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 525-533.	0.5	8
296	The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovir. <i>HIV Medicine</i> , 2014, 15, 505-510.	1.0	8
297	Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study. <i>BMC Infectious Diseases</i> , 2017, 17, 476.	1.3	8
298	The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy078.	0.4	8
299	Why do sub-Saharan Africans present late for HIV care in Switzerland?. <i>HIV Medicine</i> , 2019, 20, 418-423.	1.0	8
300	Real-life management of drug-drug interactions between antiretrovirals and statins. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1972-1980.	1.3	8
301	The influence of human genetic variation on Epstein-Barr virus sequence diversity. <i>Scientific Reports</i> , 2021, 11, 4586.	1.6	8
302	Asking about adherence - from flipping the coin to strong evidence. <i>Swiss Medical Weekly</i> , 2014, 144, w14016.	0.8	8
303	Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. <i>Aids</i> , 2007, 21, 2201-2207.	1.0	7
304	Investigating Barriers in HIV-Testing Oncology Patients: The IBITOP Study, Phase I. <i>Oncologist</i> , 2016, 21, 1176-1182.	1.9	7
305	Content analysis of antiretroviral adherence enhancing interview reports. <i>Patient Education and Counseling</i> , 2018, 101, 1676-1682.	1.0	7
306	HIV and Aging - Perhaps Not as Dramatic as We Feared?. <i>Gerontology</i> , 2018, 64, 446-456.	1.4	7

#	ARTICLE	IF	CITATIONS
307	Cost Estimates for Human Immunodeficiency Virus (HIV) Care and Patient Characteristics for Health Resource Use From Linkage of Claims Data With the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 827-833.	2.9	7
308	Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2022-2032.	1.1	7
309	Contribution of Genetic Background and Data Collection on Adverse Events of Anti-human Immunodeficiency Virus (HIV) Drugs (D:A:D) Clinical Risk Score to Chronic Kidney Disease in Swiss HIV-infected Persons With Normal Baseline Estimated Glomerular Filtration Rate. <i>Clinical Infectious Diseases</i> , 2019, 70, 890-897.	2.9	7
310	Host Genomics of the HIV-1 Reservoir Size and Its Decay Rate During Suppressive Antiretroviral Treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 517-524.	0.9	7
311	Rapid Progression of Kidney Dysfunction in People Living With HIV: Use of Polygenic and Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Risk Scores. <i>Journal of Infectious Diseases</i> , 2020, 223, 2145-2153.	1.9	7
312	Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral Therapy. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofz464.	0.4	7
313	Seasonal trivalent inactivated influenza vaccine with topical imiquimod in immunocompromised patients: A randomized controlled trial. <i>Journal of Infection</i> , 2021, 83, 354-360.	1.7	7
314	Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: a prospective cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 492-499.	1.3	7
315	HIV and solid organ transplantation: the Swiss experience. <i>Swiss Medical Weekly</i> , 2006, 136, 194-6.	0.8	7
316	Usefulness of Methadone Plasma Concentration Measurement in Patients Receiving Nevirapine or Efavirenz. <i>American Journal of Drug and Alcohol Abuse</i> , 2011, 37, 264-268.	1.1	6
317	Characteristics of HIV patients referred to a medication adherence program in Switzerland. <i>International Journal of Clinical Pharmacy</i> , 2012, 34, 426-431.	1.0	6
318	Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, dkv257.	1.3	6
319	Hepatitis C Virus Awareness Among Men Who Have Sex With Men in Southwest Switzerland. <i>Sexually Transmitted Diseases</i> , 2016, 43, 44-48.	0.8	6
320	Interferon lambda 3/4 polymorphisms are associated with AIDS-related Kaposi's sarcoma. <i>Aids</i> , 2018, 32, 2759-2765.	1.0	6
321	Quantifying the drivers of HIV transmission and prevention in men who have sex with men: a population model-based analysis in Switzerland. <i>HIV Medicine</i> , 2018, 19, 688-697.	1.0	6
322	Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort. <i>BMC Infectious Diseases</i> , 2019, 19, 834.	1.3	6
323	A Systematic Phylogenetic Approach to Study the Interaction of HIV-1 With Coinfections, Noncommunicable Diseases, and Opportunistic Diseases. <i>Journal of Infectious Diseases</i> , 2019, 220, 244-253.	1.9	6
324	Healthcare delivery for HIV-positive people with tuberculosis in Europe. <i>HIV Medicine</i> , 2021, 22, 283-293.	1.0	6

#	ARTICLE	IF	CITATIONS
325	Neurocognitive course at two-year follow-up in the neurocognitive assessment in the metabolic and aging cohort (NAMACO) study. <i>Aids</i> , 2021, Publish Ahead of Print, 2469-2480.	1.0	6
326	Assessing the drivers of syphilis among men who have sex with men in Switzerland reveals a key impact of screening frequency: A modelling study. <i>PLoS Computational Biology</i> , 2021, 17, e1009529.	1.5	6
327	Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures. <i>Antiviral Therapy</i> , 2006, 11, 53-62.	0.6	6
328	Women with HIV transitioning through menopause: Insights from the Swiss HIV Cohort Study (SHCS). <i>HIV Medicine</i> , 2022, 23, 417-425.	1.0	6
329	Disseminated histoplasmosis in Switzerland: an unexpected cause of septic shock and multiple organ dysfunction. <i>Intensive Care Medicine</i> , 2002, 28, 1501-1502.	3.9	5
330	Prolonged seroconversion in an elite controller of HIV-1 infection. <i>Journal of Clinical Virology</i> , 2009, 46, 371-373.	1.6	5
331	Vitamin D Time Profile Based on the Contribution of Non-Genetic and Genetic Factors in HIV-Infected Individuals of European Ancestry. <i>Antiviral Therapy</i> , 2015, 20, 261-269.	0.6	5
332	Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study. <i>European Journal of Clinical Investigation</i> , 2015, 45, 720-730.	1.7	5
333	Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake. <i>HIV Medicine</i> , 2015, 16, 599-607.	1.0	5
334	Contribution of Genetic Background and Clinical Risk Factors to Low-Trauma Fractures in Human Immunodeficiency Virus (HIV)-Positive Persons: The Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw101.	0.4	5
335	Are privacy-enhancing technologies for genomic data ready for the clinic? A survey of medical experts of the Swiss HIV Cohort Study. <i>Journal of Biomedical Informatics</i> , 2018, 79, 1-6.	2.5	5
336	Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?. <i>Aids</i> , 2018, 32, 205-215.	1.0	5
337	Parameter estimates for trends and patterns of excess mortality among persons on antiretroviral therapy in high-income European settings. <i>Aids</i> , 2019, 33, S271-S281.	1.0	5
338	An Adherence-Enhancing Program Increases Retention in Care in the Swiss HIV Cohort. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa323.	0.4	5
339	Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART. <i>Nature Communications</i> , 2020, 11, 5542.	5.8	5
340	Cohort-Derived Machine Learning Models for Individual Prediction of Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: A Prospective Multicenter Cohort Study. <i>Journal of Infectious Diseases</i> , 2020, 224, 1198-1208.	1.9	5
341	Influence of Drug-Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV. <i>Clinical Pharmacokinetics</i> , 2020, 59, 1037-1048.	1.6	5
342	The association between depressive symptoms and neurocognitive impairment in people with well-treated HIV in Switzerland. <i>International Journal of STD and AIDS</i> , 2021, 32, 729-739.	0.5	5

#	ARTICLE	IF	CITATIONS
343	Coronary Artery Disease-associated and Longevity-Associated Polygenic Risk Scores for Prediction of Coronary Artery Disease Events in Persons Living With Human Immunodeficiency Virus: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 1597-1604.	2.9	5
344	Increasing Frequency and Transmission of HIV-1 Non-B Subtypes Among Men Who Have Sex With Men in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2022, 225, 306-316.	1.9	5
345	Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0133879.	1.1	5
346	Imaging patterns of <i>Pneumocystis jirovecii</i> pneumonia in HIV-positive and renal transplant patients – a multicentre study. <i>Swiss Medical Weekly</i> , 2019, 149, w20130.	0.8	5
347	Lower limb high arterial flow induced by tenofovir and emtricitabine treatment. <i>Antiviral Therapy</i> , 2009, 14, 865-867.	0.6	4
348	Outcomes of Patients on Dual-Boosted PI Regimens: Experience of the Swiss HIV Cohort Study. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 1239-1246.	0.5	4
349	HIV-associated neurocognitive disorders: a changing pattern. <i>Future Neurology</i> , 2011, 6, 81-95.	0.9	4
350	AIDS defining opportunistic infections in patients with high CD4 counts in the combination antiretroviral therapy (cART) era: things ain't what they used to be. <i>Journal of the International AIDS Society</i> , 2014, 17, 19621.	1.2	4
351	Virologic and Immunologic Responses in Treatment-Naive Patients to Ritonavir-Boosted Atazanavir or Efavirenz With a Common Backbone. <i>HIV Clinical Trials</i> , 2014, 15, 92-103.	2.0	4
352	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1352-1360.	1.3	4
353	Ethnicity predicts viral rebound after travel to the tropics in HIV-infected travelers to the tropics in the Swiss HIV Cohort Study. <i>HIV Medicine</i> , 2017, 18, 564-572.	1.0	4
354	Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe. <i>HIV Medicine</i> , 2018, 19, 324-338.	1.0	4
355	Non-targeted HIV testing in the emergency department: not just <i>how</i> but <i>where</i> . <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 893-905.	2.0	4
356	The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study. <i>Antiviral Therapy</i> , 2019, 24, 343-353.	0.6	4
357	Genetic variation near CXCL12 is associated with susceptibility to HIV-related non-Hodgkin lymphoma. <i>Haematologica</i> , 2021, 106, 2233-2241.	1.7	4
358	Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV. <i>Clinical Pharmacokinetics</i> , 2021, 60, 379-390.	1.6	4
359	HIV testing in termination of pregnancy and colposcopy services: a scoping review. <i>Sexually Transmitted Infections</i> , 2022, 98, 143-149.	0.8	4
360	Epidemiology of sexually transmitted infections among female sex workers in Switzerland: a local, exploratory, cross-sectional study. <i>Swiss Medical Weekly</i> , 2020, 150, w20357.	0.8	4

#	ARTICLE	IF	CITATIONS
361	Decreasing Incidence and Determinants of Bacterial Pneumonia in People With HIV: The Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2022, 225, 1592-1600.	1.9	4
362	Active PD-L1 incorporation within HIV virions functionally impairs T follicular helper cells. <i>PLoS Pathogens</i> , 2022, 18, e1010673.	2.1	4
363	Discontinuation of Enfuvirtide in Heavily Pretreated HIV-Infected Individuals. <i>HIV Clinical Trials</i> , 2009, 10, 207-214.	2.0	3
364	Multiclass Primary Antiretroviral Drug Resistance in a Patient Presenting HIV-1/2 Dual Infection. <i>Antiviral Therapy</i> , 2012, 17, 593-594.	0.6	3
365	Impact of Recommendation Updates in Well-Controlled Patients on Nonrecommended Antiretroviral Therapies. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 180-189.	0.9	3
366	Investigating barriers in HIV-testing oncology patients. The IBITOP study: phase I. <i>Journal of the International AIDS Society</i> , 2014, 17, 19622.	1.2	3
367	HIV-1 superinfection with a triple-class drug-resistant strain in a patient successfully controlled with antiretroviral treatment. <i>Aids</i> , 2014, 28, 1840-1844.	1.0	3
368	Switching from a two-tablet regimen of tenofovir/emtricitabine and efavirenz to a one-tablet regimen may affect patients' perceptions and drug management. <i>HIV Medicine</i> , 2016, 17, 390-396.	1.0	3
369	Incidental Findings on Coronary Computed Tomography Angiography in Human Immunodeficiency Virus (HIV)-Positive and HIV-Negative Persons. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy084.	0.4	3
370	Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherence. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2468-2470.	1.3	3
371	Self-reported Neurocognitive Impairment in People Living With Human Immunodeficiency Virus (HIV): Characterizing Clusters of Patients With Similar Changes in Self-reported Neurocognitive Impairment, 2013-2017, in the Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 637-644.	2.9	3
372	HCV Genetic Diversity Can Be Used to Infer Infection Recency and Time since Infection. <i>Viruses</i> , 2020, 12, 1241.	1.5	3
373	Alcohol consumption and neurocognitive deficits in people with well-treated HIV in Switzerland. <i>PLoS ONE</i> , 2021, 16, e0246579.	1.1	3
374	Systematic screening of viral and human genetic variation identifies antiretroviral resistance and immune escape link. <i>ELife</i> , 2021, 10, .	2.8	3
375	EBV-positive large B-cell lymphoma with an unusual intravascular presentation and associated haemophagocytic syndrome in an HIV-positive patient: report of a case expanding the spectrum of EBV-positive immunodeficiency-associated lymphoproliferative disorders. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 699-705.	1.4	3
376	Identifying and Characterizing Trans Women in the Swiss HIV Cohort Study as an Epidemiologically Distinct Risk Group. <i>Clinical Infectious Diseases</i> , 2022, 74, 1468-1475.	2.9	3
377	High-dimensional immune phenotyping of blood cells by mass cytometry in patients infected with hepatitis C virus. <i>Clinical Microbiology and Infection</i> , 2022, 28, 611.e1-611.e7.	2.8	3
378	Impact of rosuvastatin on atherosclerosis in people with HIV at moderate cardiovascular risk: a randomised, controlled trial. <i>Aids</i> , 2021, 35, 619-624.	1.0	3

#	ARTICLE	IF	CITATIONS
379	Telomere Length Declines in Persons With Human Immunodeficiency Virus Before Antiretroviral Therapy Start but Not After Viral Suppression: A Longitudinal Study Over >17 Years. <i>Journal of Infectious Diseases</i> , 2022, 225, 1581-1591.	1.9	3
380	Impact of Latent Tuberculosis on Diabetes. <i>Journal of Infectious Diseases</i> , 2022, 225, 2229-2234.	1.9	3
381	A systematic molecular epidemiology screen reveals numerous HIV-1 superinfections in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2022, , .	1.9	3
382	A light in the cognitive fog?. <i>Antiviral Therapy</i> , 2013, 18, 149-151.	0.6	2
383	Comparison of Population Pharmacokinetics Based on Steady-State Assumption Versus Electronically Monitored Adherence to Lopinavir, Atazanavir, Efavirenz, and Etravirine: A Retrospective Study. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 506-515.	1.0	2
384	Mining for pairs: shared clinic visit dates identify steady <sc>HIV</sc>-positive partnerships. <i>HIV Medicine</i> , 2017, 18, 667-676.	1.0	2
385	Aging does not impact drug–drug interaction magnitudes with antiretrovirals. <i>Aids</i> , 2020, 34, 949-952.	1.0	2
386	The Role of Human Immunodeficiency Virus (HIV) Asymptomatic Status When Starting Antiretroviral Therapy on Adherence and Treatment Outcomes and Implications for Test and Treat: The Swiss HIV Cohort Study. <i>Clinical Infectious Diseases</i> , 2021, 72, 1413-1421.	2.9	2
387	Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 979-987.	0.8	2
388	Data linkage to evaluate the long-term risk of HIV infection in individuals seeking post-exposure prophylaxis. <i>Nature Communications</i> , 2021, 12, 1219.	5.8	2
389	Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study. <i>HIV Medicine</i> , 2021, 22, 623-628.	1.0	2
390	Using longitudinally sampled viral nucleotide sequences to characterize the drivers of HIV-1 transmission. <i>HIV Medicine</i> , 2021, 22, 346-359.	1.0	2
391	Differences in Social and Mental Well-Being of Long-Term Survivors among People who Inject Drugs and Other Participants in the Swiss HIV Cohort Study: 1980–2018. <i>Antiviral Therapy</i> , 2020, 25, 43-54.	0.6	2
392	The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study. <i>HIV Medicine</i> , 2022, 23, 585-598.	1.0	2
393	A 48-Year-Old Man with Laryngeal Mass and Vocal Cord Palsy. <i>Clinical Infectious Diseases</i> , 2010, 50, 1680-1681.	2.9	1
394	Rivastigmine decreases brain damage in <sc>HIV</sc> patients with mild cognitive deficits. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 915-920.	1.7	1
395	A prospective multicentre study of healthcare provider preference in rapid HIV testing kits: Determine versus INSTI. <i>International Journal of STD and AIDS</i> , 2018, 29, 51-56.	0.5	1
396	Authors'™ reply to A. Winston, A. Cotter, M. Gisslen, P. W. G. Mallon and P. Cinque. <i>HIV Medicine</i> , 2020, 21, e19-e20.	1.0	1

#	ARTICLE	IF	CITATIONS
397	OUP accepted manuscript. <i>Clinical Infectious Diseases</i> , 2021, 73, 2361-2364.	2.9	1
398	Cardiovascular risk assessment in people living with HIV compared to the general population. <i>European Heart Journal</i> , 2021, 42, .	1.0	1
399	Non-AIDS defining malignancies in the combination ART era: immunological and socio-behavioral risk factors. <i>F1000Research</i> , 0, 8, 1400.	0.8	1
400	Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa470.	0.4	1
401	Severe atherosclerotic aortoiliac occlusive disease in a young HIV-infected patient. <i>Lancet Infectious Diseases</i> , The, 2008, 8, 582.	4.6	0
402	Nonrandom Distribution of Cryptic Repeating Triplets of Purines and Pyrimidines (RNY) _n in gp120 of HIV Type1. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 493-504.	0.5	0
403	Interventions to improve adherence to drug treatment. , 2016, , 381-391.		0
404	Effect of national HIV testing recommendations and local interventions on HIV testing practices in a Swiss university hospital: a retrospective analysis between 2012 and 2015. <i>BMJ Open</i> , 2018, 8, e021203.	0.8	0
405	HIV Transmission Chains Exhibit Greater HLA-B Homogeneity Than Randomly Expected. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 81, 508-515.	0.9	0
406	Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir-based regimens in SIMPL'HIV clinical trial. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4455-4460.	1.1	0
407	Similar but different: Integrated phylogenetic analysis of Austrian and Swiss HIV-1 sequences reveal differences in transmission patterns of the local HIV-1 epidemics. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, Publish Ahead of Print, .	0.9	0
408	Title is missing!. , 2020, 17, e1003421.		0
409	Title is missing!. , 2020, 17, e1003421.		0
410	Title is missing!. , 2020, 17, e1003421.		0
411	Title is missing!. , 2020, 17, e1003421.		0
412	Title is missing!. , 2020, 17, e1003421.		0
413	Title is missing!. , 2020, 17, e1003421.		0
414	Role of the HIV-1 Reservoir to Maintain Viral Suppression in a Simplified Strategy for the Long-Term Management of HIV-1 Infection (The SIMPLâ€™HIV Trial). <i>Frontiers in Virology</i> , 0, 2, .	0.7	0